Bicara Therapeutics Inc. BCAX R2KR3KPHARMA
Company Overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.25.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +55.43% |
| 6 Months: | -22.90% |
| 3 Months: | -34.83% |
| 1 Month: | -14.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross2d ago
- RSI (14)40.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 42.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAX Bicara Therapeutics Inc. R2KR3KPHARMA | 17.61 | -5.72 | $1.17B | 0.00% | -38.70% | -41.01% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 41.79M | 32.02M | 40.68M | 41.12M | 60.24M |
| Operating Income | - | - | -9.53M | -15.37M | -19.75M | -20.63M | -41.79M | -32.02M | -40.68M | -41.12M | -60.24M |
| EBITDA | - | - | - | - | - | - | -41.77M | -32.00M | -40.65M | -41.08M | -60.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -36.77M | -27.34M | -36.29M | -37.33M | -56.16M |
| Tax Provision | - | - | - | - | - | - | 72.00K | 52.00K | 40.00K | 53.00K | 52.00K |
| Net Income | -7.41M | -9.29M | -22.84M | -12.51M | -17.05M | -17.48M | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M |
| Diluted EPS | - | - | -38.23 | -18.94 | -19.01 | -1.60 | -0.68 | -0.50 | -0.67 | -0.68 | -0.93 |
| R&D Expense | - | - | 6.90M | 12.00M | 15.80M | 15.90M | 34.30M | 24.80M | 33.00M | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.60M |
| Operating Income | -37.66M | -39.89M | -82.39M | -155.60M |
| EBITDA | -37.72M | -39.87M | -82.33M | -155.50M |
| Interest Expense | 112.00K | 0 | - | - |
| Pretax Income | -37.84M | -51.98M | -67.81M | -137.73M |
| Tax Provision | 1.00K | 5.00K | 187.00K | 217.00K |
| Net Income | -37.84M | -51.98M | -68.00M | -137.95M |
| Diluted EPS | -2.45 | -1.53 | -4.05 | -2.52 |
| R&D Expense | - | 30.60M | 63.60M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 6.70M | 233.98M | 510.00M | 430.99M |
| Current Assets | 4.98M | 231.07M | 502.53M | 422.05M |
| Cash & Equivalents | 4.16M | 230.44M | 489.71M | 96.69M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 105.51M | 382.75M | 18.12M | 29.54M |
| Current Liabilities | 23.90M | 15.09M | 17.99M | 28.95M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 657.00K | 738.00K | 1.71M |
| Total Equity | -98.80M | -148.77M | 491.88M | 401.45M |
| Shares Outstanding | 51.76M | 51.76M | 54.44M | 56.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -32.08M | -45.63M | -74.75M | -106.83M |
| Investing Cash Flow | -192.00K | -586.00K | -9.00K | -318.45M |
| Financing Cash Flow | 31.70M | 272.50M | 334.03M | 32.26M |
| Capital Expenditure | -192.00K | -586.00K | -71.00K | -280.00K |
| Free Cash Flow | -32.27M | -46.21M | -74.82M | -107.11M |
| Net Change in Cash | -573.00K | 226.28M | 259.27M | -393.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 38.3% | 34.9% | -13.8% | -34.4% |
| ROCE % | 219.0% | -18.2% | -16.7% | -38.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 10.97% | 7.26M | $126.98M |
| 2 | T. Rowe Price Investment Management, Inc. | 9.58% | 6.34M | $110.92M |
| 3 | Siren, L.L.C. | 8.47% | 5.60M | $98.05M |
| 4 | Vestal Point Capital, LP | 7.93% | 5.25M | $91.88M |
| 5 | Deep Track Capital, Lp | 6.20% | 4.10M | $71.75M |
| 6 | Blackrock Inc. | 5.82% | 3.85M | $67.34M |
| 7 | Jupiter Topco LLC | 4.79% | 3.17M | $55.49M |
| 8 | Red Tree Management, LLC | 4.78% | 3.16M | $55.36M |
| 9 | TPG GP A, LLC | 4.55% | 3.01M | $52.68M |
| 10 | Vanguard Capital Management LLC | 3.35% | 2.22M | $38.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCAX
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5JdTRhNjlsMVBOTnZibVFYeHVnUTZjZGkxYmUzVjh0Qm94Z1kwOG5Kcm1idVJnaHBrbzU3bFc1eFdaei1Id0hlWUJjam40c0FS?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNNjlPWHFubVhRX3VLV1J2cVpIM1pRWmNvbHlHOGhpUFJhSnEzQ3JUcF9MeEVVbk9vUmoyTG93eDVXTm9Od0FKUnVWTGFraF9vZHRfaWZkV3lvdk5jeVdlcUtLcmZ2RXhQWWlqbUdDYTZGeWo5VllCNERmUUMzME9CQnZKbUR0U3hxQkdiN1…
BCAX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE11MUUydWZwZExtQjhqLWVfVmMwZVhreE5MeHBkNU5rVTV0UWZINi1rTzB4aHhLUXhfNHhlYWwzR3B4WE05WGJ4SzF6SUdnOG53YUJzbnAxVXpVUm1BbVNGZm8zRzVSeGdlWUFHcGVYZUVIendFZkxBQ2dR?oc=5" target="_blank">BCA…
Morgan Stanley initiates Bicara Therapeutics stock with overweight rating By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPTjVQdkRrcDJFSEQ4cmN0MVBpRVk2cEEtaWVwT1piY1h0azZCVkg1d1lWWXVqWml2cUN4RDJPYWozaFg2cC1TWWJGWjdCbWtMZklMSFl0cm9vTnl1X2hQcF9wOWlNZ1dESzU1UEVURW1qc2hkM1gwU3ZpaktMVmZzckM3VHRKT3pDUXFKSG…
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds (NASDAQ:BCAX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQVFZfRlotMlZURHBEYnp3ZFkzQjRtU0VkYU9KVi1fazBpZU9FdlhWLUNtN3VLRzBEWGZLeThsdjljMktWRGlyWm1vR3hORVR4UFZBTzJWenV2M09DSUdwMkw1RDhuM29DTFZHUmFkck9HUmZZTVVvU3N5X0xHVnpkLW9ZeDBIMmtDaVhsXz…
BCAX Dec 2026 17.500 put (BCAX261218P00017500) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5DWDIydzBva2t3Tlp4dFFFa0tDNVZZY1o5ZDEwUk03TU43TVlSOGs1czh5b0hmdHdkX3drcTR4YjgyUjNhSTZlWlBpczd0QWNYVnF5WXRNSGJDOGs1ZHNWT1FMX29VM2RBX2prZFdR?oc=5" target="_blank">BCAX Dec 2026 17.50…
BCAX — Frequently Asked Questions
What is the current share price of Bicara Therapeutics Inc. (BCAX)?
As of 2026-10-22 16:30 PDT, Bicara Therapeutics Inc. (BCAX) trades at $17.61 on NasdaqGM. Its 52-week range is $10.44 to $30.40.
What is the market capitalisation of BCAX?
Bicara Therapeutics Inc. (BCAX) has a market capitalisation of $1.17B on NasdaqGM.
What is the P/E ratio of BCAX?
BCAX trades at a trailing price-to-earnings (P/E) ratio of -5.72. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 2.46.
What is the return on equity (ROE) of BCAX?
BCAX has a return on equity (ROE) of -41.01%. Its return on capital employed (ROCE) is -38.70%.
Is BCAX a good stock to buy?
This page provides a data-driven analysis of Bicara Therapeutics Inc. (BCAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.